News

Aug. 28. 2019

MHLW Approves Additional Indications for CANDESARTAN Tablets and OD Tablets2

Aug. 15. 2019

Sawai Receives Approvals for Two Generic Drugs with Five Strengths

Jul. 23. 2019

Sawai Selected for FTSE4Good and FTSE Blossom Japan Indexes

Jul. 22. 2019

Upsher-Smith Laboratories Completes Acquisition of Two Treatments for Acute Migraine in Adults

Jun. 21. 2019

Osteoporosis drug "Minodronic Acid Tablets 50 mg [SAWAI]" wins "World Star Awards" in a prestigious packaging contest.

Jun. 18. 2019

MHLW Approves Additional Indications for METHOTREXATE Capsules

Jun. 14. 2019

Upsher-Smith Laboratories Enters Into Agreement to Acquire Tosymra^™ and Zembrace^® Symtouch^®

Jun. 13. 2019

Sawai Launches Three Generic Drugs with Seven Strengths

Jun. 05. 2019

MHLW Approves Additional Indication for LINEZOLID Injection and Tablets

Mar. 28. 2019

Upsher-Smith Launches Generic Version of Prozac^® (Fluoxetine) Tablets

Mar. 27. 2019

MHLW Approves New Indication for DONEPEZIL Tablets, OD Tablets and Fine Granules

Mar. 06. 2019

MHLW Approves New Indication for ARIPIPRAZOLE Tablets and Oral Solution

Feb. 20. 2019

Upsher-Smith Laboratories, LLC celebrates its 100-year anniversary.

Feb. 15. 2019

Sawai Receives Approvals for Three Generic Drugs with Six Strengths

Feb. 13. 2019

An interview with Mitsuo Sawai (President of Sawai Pharmaceutical Co., Ltd.) was published in 2019 Japan Business Report in the South China Morning Post.

Jan. 09. 2019

MHLW Approves New Indication for ARGATROBAN Injection

Dec. 13. 2018

Sawai Launches Six Generic Drugs with 14 Strengths

Dec. 05. 2018

MHLW Approves New Indication for RISEDRONATE Tablets and DOBUTAMINE I.V. Infusion

Nov. 21. 2018

MHLW Approves New Indication for LEVOFOLINATE I.V. Infusion

Oct. 24. 2018

Upsher-Smith Launches Generic Version of ONFI^® (Clobazam), CIV In Tablet And Oral Suspension Dosage Forms

Sep. 21. 2018

Sawai Pharmaceutical Receives Public Knowledge-Based Applications for Anti-Cancer Agent OXALIPLATIN I.V. Infusion Solution for Additional Indication

Sep. 05. 2018

MHLW Approves New Indication for ARIPIPRAZOLE Tablets 3 mg / 6 mg / 12 mg / 24 mg [SAWAI] and ARIPIPRAZOLE Oral Solution 3 mg / 6 mg / 12 mg Packet [SAWAI]

Sep. 03. 2018

Upsher-Smith Launches Generic Version of Lomotil^® (Diphenoxylate Hydrochloride and Atropine Sulfate) Tablets

Aug. 16. 2018

Sawai Pharmaceutical Receives Approvals for Six Compounds with 13 Strengths of Generic Drugs